MetaCap

Editas Medicine Inc. (EDIT)

NASDAQ: EDITHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

1.64-0.07 (-4.09%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

EDIT stock chart

Technical analysis

Key statistics

All statistics
Market cap
$253.12M
EPS (TTM)
-$0.54
52-week range
1.63 – 3.94
Day range
1.63 – 1.78
Volume / Avg
2.68M / 2.63M
Beta
—

52-week range

$1.63$3.94

EDIT stock today

Shares of Editas Medicine (EDIT) finished lower on Nov 20 at $1.64, a drop of 4.09% or $0.07 per share, versus the S&P 500's 3.70% decline. At this level, EDIT sits near the bottom of its 52-week range of $1.63 to $3.94: 58.4% below the high, set on May 27, 2026 and 0.6% above the low. EDIT is down 20.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 32.2%.

Editas Medicine has posted a net loss over the last twelve months (EPS of -$0.54), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Editas Medicine

Company profile

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Gilmore O'Neill M.D.
Headquarters
Cambridge, MA
Employees
87
IPO year
2016

Financial highlights

Full financials

In fiscal 2025, Editas Medicine generated $40.5 million in revenue, up 25.4% from fiscal 2024. Editas Medicine reported a net loss of $160.1 million, compared with a loss of $237.1 million a year earlier. Operating margin was -394.9%.

Editas Medicine annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$40.52M$32.31M$78.12M$19.71M$25.54M
Growth+25.39%-58.64%+296.32%-22.83%-71.85%
Net income$-160.06M$-237.09M$-153.22M$-220.43M$-192.50M
EPS (diluted)$-1.80$-2.88$-2.02$-3.21$-2.85

Analyst forecast

Forecast

Consensus (13 analysts)

buy

Avg. price target

$6.10+271.95%

  • Strong buy 0
  • Buy 9
  • Hold 2
  • Sell 0
  • Strong sell 2

Target range

Low $1.00High $15.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$-0.15 vs $-0.21
Surprise
+28.57%

EDIT news

All EDIT news

Editas Medicine peers

Health Care sector
EDIT peer companies
CompanyPrice% ChgMarket capCompare
SABSSAB Biotherapeutics Inc.2.81-3.44%$253.15Mvs EDIT
EIKNEikon Therapeutics Inc.4.74-0.42%$256.84Mvs EDIT
OCGNOcugen Inc.0.7679+4.79%$260.55Mvs EDIT
LXEOLexeo Therapeutics Inc.2.96+0.34%$245.05Mvs EDIT
PLXProtalix BioTherapeutics Inc. (DE)2.90-5.23%$244.52Mvs EDIT
AUTLAutolus Therapeutics plc ADR0.9073-7.38%$241.65Mvs EDIT
AGMBAgomAb Therapeutics NV ADR5.45-3.02%$268.40Mvs EDIT
KYTXKyverna Therapeutics Inc.4.26-2.52%$269.33Mvs EDIT

Indexes, lists and sector

Editas Medicine stock FAQ

What is Editas Medicine's stock price today?

EDIT last traded at $1.64 as of Nov 20, 4:00 PM EST, down 4.09% on the day. Prices are delayed at least 15 minutes.

Who is Editas Medicine's CEO?

Dr. Gilmore O'Neill M.D. is the chief executive officer of Editas Medicine Inc., which has about 87 employees.

What is the EDIT 52-week high?

The 52-week high for EDIT is $3.94 and the 52-week low is $1.63. The stock is currently 58.4% below its high.

Compare EDIT